Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bidridistrogene xeboparvovec - Myonexus Therapeutics

Next Previous
Drug Profile

Bidridistrogene xeboparvovec - Myonexus Therapeutics

Alternative Names: MYO-101; rAAVrh74.MHCK7.hSGCB; rAAVrh74.MHCK7.SGCB; scAAVrh74.MHCK7.hSGCB; scAAVrh74.tMCK.hSGCB; SRP-9003

Latest Information Update: 22 Jul 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Nationwide Children's Hospital
  • Developer Myonexus Therapeutics; Nationwide Children's Hospital; Sarepta Therapeutics
  • Class Gene therapies
  • Mechanism of Action Sarcoglycan expression stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Limb girdle muscular dystrophies
  • New Molecular Entity No

Highest Development Phases

  • Phase III Limb girdle muscular dystrophies

Most Recent Events

  • 18 Jul 2025 US FDA places clinical hold on all clinical trials for limb girdle muscular dystrophy using AAVrh74 gene therapies
  • 04 Jun 2025 US FDA grants platform technology designation for rAAVrh74 viral vector used in bidridistrogene xeboparvovec for Limb-girdle muscular dystrophy
  • 15 Apr 2025 Sarepta Therapeutics announces intention to submit BLA to the US FDA for accelerated approval for SRP 9003 in the second half of 2025

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top